Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.49 |
| ▸ | FNTA | P49354 | 2/20 | 0.45 |
| ▸ | FNTB | P49356 | 2/20 | 0.45 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.45 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30296901 | 1.00 | FOLH1 (0.54) | FOLH1GSRCPB2FNTAFNTB | |
| SCHEMBL12273787 | 1.00 | FOLH1 (0.54) | FOLH1GSRCPB2FNTAFNTB | |
| SCHEMBL9442197 | 1.00 | FOLH1 (0.54) | FOLH1GSRCPB2FNTAFNTB | |
| SCHEMBL12504560 | 1.00 | FOLH1 (0.54) | FOLH1GSRCPB2FNTAFNTB | |
| SCHEMBL23857928 | 0.97 | FOLH1 (0.51) | FOLH1GSRCPB2FNTAFNTB | |
| SCHEMBL30856932 | 0.97 | FOLH1 (0.51) | FOLH1GSRCPB2FNTAFNTB | |
| SCHEMBL30307570 | 0.97 | FOLH1 (0.51) | FOLH1GSRCPB2FNTAFNTB | |
| SCHEMBL29642982 | 0.97 | FOLH1 (0.51) | FOLH1GSRCPB2FNTAFNTB | |
| SCHEMBL31520392 | 0.97 | FOLH1 (0.51) | FOLH1GSRCPB2FNTAFNTB | |
| SCHEMBL30307583 | 0.97 | FOLH1 (0.51) | FOLH1GSRCPB2FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-26 | — | — | US | claimed |
| EP-4610269-A1 | UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE | 3B Pharmaceuticals GmbH (DE) | 2025-09-03 | — | — | EP | claimed |
| EP-4583917-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2025-07-16 | — | — | EP | claimed |
| CN-120192431-A | Self-assembled polypeptide probe for enhancing tumor magnetic resonance imaging | 东南大学 | 2025-06-24 | — | — | CN | claimed |
| CN-119923279-A | Prostate Specific Membrane Antigen (PSMA) ligands and uses thereof | 3B制药有限公司 | 2025-05-02 | — | — | CN | claimed |
| CN-114685645-B | Synthetic method of somalupeptide | 深圳翰宇药业股份有限公司 | 2025-03-21 | — | — | CN | claimed |
| US-20240279615-A1 | COMPOSITIONS COMPRISING DIPEPTIDES AND TRACE ELEMENTS | EVONIK OPERATIONS GMBH (DE) | 2024-08-22 | — | — | US | claimed |
| EP-4402246-A1 | COMPOSITIONS COMPRISING DIPEPTIDES AND TRACE ELEMENTS | Evonik Operations GmbH (DE) | 2024-07-24 | — | — | EP | claimed |
| CN-117940556-A | Composition comprising dipeptide and trace element | 赢创运营有限公司 | 2024-04-26 | — | — | CN | claimed |
| WO-2024052431-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2024-03-14 | — | — | WO | claimed |
| EP-4166651-A1 | METHODS AND COMPOSITION TO INCREASE CELLULAR GLUTATHIONE LEVEL | Evonik Operations GmbH (DE) | 2023-04-19 | — | — | EP | claimed |
| WO-2023041295-A1 | COMPOSITIONS COMPRISING DIPEPTIDES AND TRACE ELEMENTS | EVONIK OPERATIONS GMBH (DE) | 2023-03-23 | — | — | WO | claimed |
| EP-4138771-A1 | COMPOSITIONS COMPRISING CYS-PEPTIDES | Evonik Operations GmbH (DE) | 2023-03-01 | — | — | EP | claimed |
| CN-115397388-A | Compositions comprising CYS-peptides | 赢创运营有限公司 | 2022-11-25 | — | — | CN | claimed |
| US-8658394-B2 | Methods, cells and systems for incorporating non-canonical amino acids into proteins | WATERSTONE PHARMACEUTICALS (CN) | 2014-02-25 | — | — | US | claimed |
| US-20120237971-A1 | METHODS, CELLS AND SYSTEMS FOR INCORPORATING NON-CANONICAL AMINO ACIDS INTO PROTEINS | WATERSTONE PHARMACEUTICALS (CN) | 2012-09-20 | — | — | US | claimed |
| WO-2012092629-A2 | METHODS, CELLS, AND SYSTEMS FOR INCORPORATING NON-CANONICAL AMINO ACIDS INTO PROTEINS | WATERSTONE PHARMACEUTICALS (CN) | 2012-07-05 | — | — | WO | claimed |
| EP-0460189-A4 | PRODUCTION OF BIOLOGICALLY ACTIVE PLATELET-DERIVED GROWTH FACTOR FROM HIGH EXPRESSION HOST CELL SYSTEMS | — | 1993-05-26 | — | — | EP | claimed |
| EP-0460189-A1 | PRODUCTION OF BIOLOGICALLY ACTIVE PLATELET-DERIVED GROWTH FACTOR FROM HIGH EXPRESSION HOST CELL SYSTEMS | AMGEN INC. (US) | 1991-12-11 | — | — | EP | claimed |
| WO-1991008762-A1 | PRODUCTION OF BIOLOGICALLY ACTIVE PLATELET-DERIVED GROWTH FACTOR FROM HIGH EXPRESSION HOST CELL SYSTEMS | AMGEN INC. (US) | 1991-06-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | KLK3, FOLH1, PSMA1 | FOLH1 2/4885GSR 2457/4885CPB2 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.